Italian court upholds Aspen excessive pricing decision
An Italian court has upheld the Italian Antitrust Authority's decision to fine pharmaceutical company Aspen €5 million for abuse of dominance, backing the enforcer's benchmark for assessing whether the company had unfairly inflated the prices of cancer drugs.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.